| Citation: |
WANG Ping, YANG Wenxiu, ZHOU Jie, FENG Jianglong, LIN Chaoqun. Expression of PD-L1 and Its Clinical Significance in MYC/BCL2 Double-expression Large B Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(1): 32-36. DOI: 10.3971/j.issn.1000-8578.2020.19.0957
|
To investigate the correlation between MYC/BCL2 double-expression large B cell lymphoma (DEL) and programmed cell death ligand 1 (PD-L1) mRNA or protein expressions and analyze the clinical significance of PD-L1 protein expression in DEL.
We collected 90 cases of diffuse large B-cell lymphoma(DLBCL) and detected MYC and BCL2 protein by immunohistochemical staining, and then grouped them into DEL and non-DEL groups. The expressions of PD-L1 in tumor cells or microenvironment were detected by immunohistochemical double labeling staining. qPCR was used to detect the relative expression of PD-L1 mRNA. The clinicopathological data were collected and followed up.
Among 90 cases of DLBCL, there were 28 cases of DEL, 22 cases of PD-L1 expression in tumor cells (PD-L1+) and 26 cases in microenvironment (mPD-L1+); while, 14 cases of PD-L1 expression in tumor cells and 9 cases in microenvironment in DEL group. PD-L1 protein expression in tumor cells or microenvironment was correlated with DEL (P < 0.05). The relative expression of PD-L1 mRNA was significantly different between two groups (P=0.012). PD-L1+ was related to IPI score and B symptom in DEL group (P=0.007, 0.021). PD-L1+ and mPD-L1+ were correlated with the prognosis of patients in DEL group (P=0.005, 0.001).
The mRNA and protein expression of PD-L1 are significantly up-regulated in DEL patients and correlated with the prognosis. PD-L1 could be used as an independent risk factor for the evaluation of poor prognosis of DEL patients.
| [1] |
Friedberg JW. How I treat double-hit lymphoma[J]. Blood, 2017, 130(5):590-596. doi: 10.1182/blood-2017-04-737320
|
| [2] |
Kawashima I, Inamoto Y, Maeshima AM, et al. Double expressor lymphoma is associated with poor outcomes after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(2):294-300. doi: 10.1016/j.bbmt.2017.10.013
|
| [3] |
Reagan PM, Davies A. Current treatment of double hit and double expressor lymphoma[J]. Hematology Am Soc Hematol Educ Program, 2017, 2017(1):295-297. doi: 10.1182/asheducation-2017.1.295
|
| [4] |
Riedell PA, Smith SM. Double hit and double expressors in lymphoma:Definition and treatment[J]. Cancer, 2018, 124(3):4622-4632.
|
| [5] |
Herrera AF, Mei M, Low L, et al. Relapsed or refractory doubleexpressor and double-hit lymphomas have inferior progressionfree survival after autologous stem-cell transplantation[J]. J Clin Oncol, 2017, 35(1):24-31. doi: 10.1200/JCO.2016.68.2740
|
| [6] |
吴辉菁, 于丁, 杨业勤, 等. ABVD成功解救难治性弥漫大B细胞淋巴瘤1例报道[J].肿瘤防治研究, 2016, 43(11):1008-1010. doi: 10.3971/j.issn.1000-8578.2016.11.018
Wu HJ, Yu D, Yang YQ, et al. Sucessful salvage therapy with ABVD on refractory diffuse large B-cell lymphoma:A case report[J]. Zhong Liu Fang Zhi Yan Jiu, 2016, 43(11):1008-1010. doi: 10.3971/j.issn.1000-8578.2016.11.018
|
| [7] |
Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells[J]. J Exp Med, 2009, 206(13):3015-3029. doi: 10.1084/jem.20090847
|
| [8] |
Topalian SL, Hodi FS, Brahmer JR, et a1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. New Engl J Med, 2012, 366(26):2443-2454. doi: 10.1056/NEJMoa1200690
|
| [9] |
Casey SC, Tong L, Li Y, et al. MYC regulates the anti-tumor immune response through CD47 and PD-L1[J]. Science, 2016, 352(6282):227-231. doi: 10.1126/science.aac9935
|
| [10] |
Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo[J].Blood Cells Mol Dis, 2001, 27(1):206-216. doi: 10.1006-bcmd.2000.0372/
|
| [11] |
Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2:translating cell death discoveries into novel cancer therapies[J]. Nat Rev Cancer, 2016, 16(2):99-109. doi: 10.1038/nrc.2015.17
|
| [12] |
Green TM, Nielsen O, De Stricker K, et al. High Levels of Nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma[J]. Am J Surg Pathol, 2012, 36(4):612-619. doi: 10.1097/PAS.0b013e318244e2ba
|
| [13] |
Bogusz AM, Kovach AE, Le LP, et al. Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling byquantitative immunofluorescence[J]. PLoS One, 2017, 12(2):1-14. https://www.ncbi.nlm.nih.gov/pubmed/28212447
|
| [14] |
尹文娟, 朱秀, 杨海燕, 等.原发中枢神经系统弥漫性大B细胞淋巴瘤中bcl-2、C-MYC基因异常、蛋白表达及治疗方案选择对患者预后的影响[J].中华病理学杂志, 2018, 47(1):32-38. doi: 10.3760/cma.j.issn.0529-5807.2018.01.007
Yin WJ, Zhu X, Yang HY, et al. Effects of bcl-2 and c-myc gene abnormalities, protein expression and treatment protocol selection on prognosis of patients with primary diffuse large B cell lymphoma of central nervous system[J]. Zhonghua Bing Li Xue Za Zhi, 2018, 47(1):32-38. doi: 10.3760/cma.j.issn.0529-5807.2018.01.007
|
| [15] |
Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma[J]. Blood, 2015, 126(19):2193-2201. doi: 10.1182/blood-2015-02-629600
|
| [16] |
Liu Y, Ma J, Yu K, et al. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas[J]. Pathol Res Pract, 2018, 214(4):507-512. doi: 10.1016/j.prp.2018.03.001
|
| [17] |
Sun C, Jia Y, Wang W, et al. Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma[J]. Histopathology, 2019, 74(4):618-628. doi: 10.1111/his.13765
|
| [18] |
Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall sur vival in aggressive diffuse large B-cell lymphoma:results from a French multicenter clinical trial[J]. Leukemia, 2014, 28(12):2367-2375. doi: 10.1038/leu.2014.137
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: